Enter your keyword

Assessment of Lekhana Basti in the Management of Hyperlipidemia

Beautifully suited for all your web-based needs

Assessment of Lekhana Basti in the Management of Hyperlipidemia

Assessment of Lekhana Basti in the Management of Hyperlipidemia

Hyperlipidemia is highly prevalent and is closely related to coronary heart disease which is the most common cause of death. Raised cholesterol is estimated to be responsible for 18% of cerebrovascular disease and 56% of ischemic heart disease. Overall, these diseases account for about 4.4 million deaths (7.9% of the total). Based upon the etiological factors and symptom complexes, hyperlipidemia can be considered as a part of Medoroga. Being a Tikshna formulation, the treatment modality of Lekhana Basti is aimed basically for Apatarpana (emaciation) of the body, as Basti is the fastest Apatarpana. In the present clinical trial, a total of 22 patients were registered of whom 19 patients completed the course of the therapy. Under randomization, the registered patients were divided into two roups of which group A was treated with Lekhana Basti and group B was administered standard control drug, i.e., Triphala Guggulu, for 21 days. The results of the study revealed that in patients treaed with Lkhana Basti, there was a decrease of about 4.99% in S. cholesterol, 9.13% in S. low density lipoprotein (LDL), and 0.36% in S. apolipoprotein B. Lekhana Basti was found to have significant Eeffect in reducing the symptoms of Medodushti and in reduction of objective parameters like weight, body mass index (BMI), body fat percentage, body circumfereces such as chest, abdomen, hip, pelvis, mid‑thigh circumference, etc., and skin fold thickness as biceps, triceps, mid‑arm, and abdominal skinfold thickness.

Access this article online

Website: www.ayujournal.org

No Comments

Post a Comment

Your email address will not be published.